Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Axsome Therapeutics Q1 2024 GAAP EPS $(1.44) Misses $(1.21) Estimate, Sales $74.999M Beat $73.295M Estimate

Author: Benzinga Newsdesk | May 06, 2024 07:01am
Axsome Therapeutics (NASDAQ:AXSM) reported quarterly losses of $(1.44) per share which missed the analyst consensus estimate of $(1.21) by 19.01 percent. The company reported quarterly sales of $74.999 million which beat the analyst consensus estimate of $73.295 million by 2.32 percent. This is a 20.70 percent decrease over sales of $94.576 million the same period last year.

Posted In: AXSM


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist